Who is sponsoring NCT06097923?

NCT06097923 is sponsored by Seoul St. Mary's Hospital.

What drugs are being tested in NCT06097923?

Interventions in NCT06097923: Active fluid management with BIA monitoring, Conventional fluid management without BIA monitoring.

What condition does NCT06097923 study?

NCT06097923 studies Fluid Overload, Fluid Loss.

Is NCT06097923 still recruiting?

NCT06097923 is currently completed. Last updated 24 October 2023.

Last reviewed 2023-10-24 · How we verify

NCT06097923

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Implementation of Fluid Strategies Using Real-time Bioelectrical Analyzer in Surgical Intensive Care Unit (SICU)

Completed NA Last updated 24 October 2023

What this trial tests

NA trial testing Active fluid management with BIA monitoring in Fluid Overload in 200 participants. Completed in 31 December 2022.

Timeline

30 November 2021

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Seoul St. Mary's Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	200
Start date	30 November 2021
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across South Korea

Drugs / interventions tested

Active fluid management with BIA monitoring — full drug profile →
Conventional fluid management without BIA monitoring — full drug profile →

Conditions studied

Fluid Overload — all drugs for Fluid Overload →
Fluid Loss — all drugs for Fluid Loss →

Sponsor

Seoul St. Mary's Hospital

Who can join

18 and older, any sex, with Fluid Overload or Fluid Loss. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Precise assessment of postoperative volume status is important to administrate optimal fluid management. Bioelectrical impedance analysis (BIA) which measures the body composition using electric character. Extracellular water (ECW) ratio by BIA represented as the ratio of ECW to total body water (TBW) and is known to reflect the hydration status. Based on this, we aimed to determine whether aggressive fluid control using ECW ratio could improve clinical outcomes through a single blind, randomized controlled trial.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of rigorous fluid management using monitoring of ECW ratio by bioelectrical impedance analysis in critically ill postoperative patients: A prospective, single-blind, randomized controlled study.
Chung YJ, Lee GR, Kim HS, Kim EY. · · 2024 · cited 7× · PMID 39142110 · DOI 10.1016/j.clnu.2024.07.040

Verify or expand the search:

Other recruiting trials for Fluid Overload

Currently open trials in the same condition.

NCT03629977 — Timing of Renal Replacement Therapy in the Critically Ill Patients · recruiting
NCT07275658 — Timing and Dose of Fluid Deresuscitation in Critically Ill Patients · recruiting
NCT06697470 — Muscle and Subcutaneous Tissue Variation by Ultrasound and Impedance Linked to Fluid Balance in ICU Patients · recruiting
NCT06539026 — Inferior Vena Cava Collapsibility Index Guide for Preoperative Fluid Therapy in Preeclampsia · NA · recruiting
NCT06418022 — Evaluating Fluid Responsiveness in ICU Patients Using VTI and Trendelenburg Positioning · NA · recruiting

Other Seoul St. Mary's Hospital trials

Trials by the same sponsor.

NCT07345026 — Acellular Dermal Matrix(SureDerm BCS) in Breast-Conserving Surgery for Breast Cancer Patients · NA · not yet recruiting
NCT07380867 — Confirming the Accuracy of Endoscopic Marking Using a New Marker, a Novel Luminomarker, in Lesion Marking Before Colorec · NA · enrolling by invitation
NCT07240844 — Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy · Phase 4 · not yet recruiting
NCT06769087 — Comparing Immediate Removal and Postoperative 1 Day of Urinary Catheter After Colorectal Cancer Surgery · NA · enrolling by invitation
NCT06442111 — The Role of Intravenous Ferritin in Optimizing Postoperative Recovery Following Pancreaticoduodenectomy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06097923 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Seoul St. Mary's Hospital
Last refreshed: 24 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06097923.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing